Thalidomide and dexamethasone for newly diagnosed multiple myeloma: Is this really the standard of care?

被引：2
|
作者：
Nabhan, Chadi [1 ]
Bitran, Jacob D. [1 ]
机构：
[1] Lutheran Gen Hosp, Inst Canc, Park Ridge, IL 60068 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
10.1200/JCO.2006.06.3115
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2967 / 2968
页数：2
相关论文
共 50 条
  • [41] Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA)
    Roussel, Murielle
    Moreau, Philippe
    Hebraud, Benjamin
    Laribi, Kamel
    Jaccard, Arnaud
    Dib, Mamoun
    Slama, Borhane
    Dorvaux, Veronique
    Royer, Bruno
    Frenzel, Laurent
    Zweegman, Sonja
    Klein, Saskia K.
    Broijl, Annemiek
    Jie, Kon-Siong
    Wang, Jianping
    Vanquickelberghe, Veronique
    Boer, Carla de
    Kampfenkel, Tobias
    Gries, Katharine S.
    Fastenau, John
    Sonneveld, Pieter
    LANCET HAEMATOLOGY, 2020, 7 (12): : E874 - E883
  • [42] Lymphocyte Profiling in Newly Diagnosed Multiple Myeloma: First-Line Treatment with Cyclophosphamide, Thalidomide, Dexamethasone, and Daratumumab
    Santos, Allan
    Santos, Mariane
    Leal, Joanna
    Santos, Herbert
    Santos, Juliana
    Lucas, Larissa
    Salvino, Marco Aurelio
    Bomfim, Maria da Gloria
    Hungria, Vania
    Torres, Alex
    Crusoe, Edvan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S580 - S580
  • [43] Low-dose dexamethasone and thalidomide with higher frequency zoledronic acid (dtZ) for newly diagnosed multiple myeloma
    Teoh, G.
    Tan, D.
    Chuah, C.
    Hwang, W.
    Yiu, R.
    Kuperan, P.
    Tien, S.
    Lee, L.
    Ang, A.
    Kam, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Thalidomide, Intravenous Cyclophosphamide and Dexamethasone (ThaCyDex) in Newly Diagnosed Multiple Myeloma: Response to Therapy, Time to Progression and Survival
    Jezael Martinez-Rueda, Armando
    Maria Armillas-Canseco, Flor
    Olivas-Martinez, Antonio
    Martinez-Banos, Deborah
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S239 - S239
  • [45] Influence of stem cell mobilisation after cyclophosphamide, thalidomide and dexamethasone regimen in patients with newly diagnosed multiple myeloma
    Lee, J. J.
    Ahn, J. S.
    Yang, D. H.
    Jung, S. H.
    Song, C. E.
    Choi, G. H.
    Lee, S. Y.
    Bae, S. Y.
    Kim, Y. K.
    Kim, H. J.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S332 - S332
  • [46] A PHASE I/II TRIAL OF CYCLOPHOSPHAMIDE, CARFILZOMIB, THALIDOMIDE AND DEXAMETHASONE (CYCLONE) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Mikhael, J.
    Reeder, C.
    Libby, E.
    Costa, L.
    Mayo, A.
    Bergsagel, L.
    Buadi, F.
    Pirooz, N.
    Lubben, J.
    Dueck, A.
    Stewart, A.
    HAEMATOLOGICA, 2012, 97 : 119 - 119
  • [47] HEMATOLOGY Setting the standard for newly diagnosed multiple myeloma
    Laubach, Jacob
    Richardson, Paul G.
    Anderson, Kenneth
    NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (05) : 255 - 256
  • [48] Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
    Kumar, Shaji K.
    Kapoor, Prashant
    Laplant, Betsy
    Phuong-Dung, Liang
    Muchtar, Eli
    Buadi, Francis K.
    Gonsalves, Wilson I.
    Malave, Gabriella C.
    Vossen, Alanna M.
    Dingli, David
    Go, Ronald S.
    Warsame, Rahma M.
    Kourelis, Taxiarchis
    Hwa, Yi L.
    Fonder, Amie
    Hobbs, Miriam A.
    Lust, John A.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Leung, Nelson
    Rajkumar, S. Vincent
    Gertz, Morie A.
    BLOOD, 2020, 136
  • [49] Thalidomide increases the activity of melphalan/prednisone in newly diagnosed multiple myeloma
    不详
    CLINICAL LYMPHOMA, 2004, 5 (02): : 76 - 77
  • [50] Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
    Zafar, Mir Sadaqat Hassan
    Khan, Afaq Ahmed
    Aggarwal, Shyam
    Bhargava, Manorama
    SOUTH ASIAN JOURNAL OF CANCER, 2018, 7 (01) : 58 - 60
12345